Fondazione del Piemonte per l'Oncologia-IRCCS Candiolo Trials

Fondazione del Piemonte per l'Oncologia-IRCCS Candiolo	Welcome, Profile Billing Logout

Trial + Data / Events

Status

Region

Interventions

Sponsor

Conditions

Primary compl

Study compl

Montemurro, Filippo

ZEST, NCT04915755 / 2020-003973-23: Efficacy and Safety Comparison of Niraparib to Placebo in Participants With Human Epidermal Growth Factor 2 Negative (HER2-) Breast Cancer Susceptibility Gene Mutation (BRCAmut) or Triple-Negative Breast Cancer (TNBC) With Molecular Disease

Jan 2025 - Dec 2025: Pivotal data from ZEST trial for HER2-negative BRCA-mutated or triple-negative breast cancer

Active, not recruiting

Europe, Canada, Japan, US, RoW

Niraparib, Placebo

GlaxoSmithKline

Neoplasms, Breast

06/24

12/25

EMBER-4, NCT05514054: A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer

Recruiting

8000

Europe, Canada, Japan, US, RoW

Imlunestrant, LY3484356, Tamoxifen, Anastrozole, Letrozole, Exemestane

Eli Lilly and Company

Breast Neoplasms

10/27

03/32

GIM24-PALBO-BP, NCT04318223 / 2019-000221-45: Palbociclib Plus Fulvestrant in Women With Hormone Receptor Positive and Human Epidermal Growth Factor Receptor Type 2 Negative Locally Advanced or Metastatic Breast Cancer Previously Treated With a CDK4/6 Inhibitor in Combination With Hormonal Therapy

Recruiting

168

Europe

Palbociclib

Consorzio Oncotech

Metastatic Breast Cancer, Locally Advanced Breast Cancer

07/23

BIO-META, NCT02284581: Evaluation of Medical Treatments in MBC Patients According Biological Subtype and Line of Treatments

Recruiting

N/A

10000

Europe

Consorzio Oncotech

Metastatic Breast Cancer

06/23

12/25

IRMO, NCT06337019: The Italian Registry of Malnutrition in Oncology

Recruiting

N/A

1500

Europe

Cohort observational

Fondazione IRCCS Policlinico San Matteo di Pavia, Istituto di Ricerche Farmacologiche Mario Negri IRCCS

Cancer, Cancer Metastatic

10/27

PREFER-Fertility, NCT02895165: PREgnancy and FERtility Registry

Recruiting

N/A

1000

Europe

IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy, Clinical Research Technology S.r.l.

Breast Neoplasms, Pregnancy, Fertility Preservation

11/27

11/32

Galizia, Danilo

XRAY VISION, NCT05386550 / 2022-001144-18: Phase III Xevinapant (Debio 1143) and Radiotherapy in Resected LA SCCHN, High Risk, Cisplatin-ineligible Participants

Terminated

166

Europe, Canada, Japan, US, RoW

Xevinapant (Debio 1143), IMRT, Placebo

EMD Serono Research & Development Institute, Inc., Merck KGaA, Darmstadt, Germany

Head and Neck Cancer

08/24

ProcemISA, NCT04398524 / 2020-003652-32: A Phase II Study of Cemiplimab and ISA101b in Patients With Recurrent/Metastatic HPV16 Positive OPC

May 2024 - Jul 2024 : Mid'24 - Data from ISA101b-OPC-03-19 study in recurrent metastatic HPV16 induced HNC

Active, not recruiting

Europe, US, RoW

ISA101b, Cemiplimab

ISA Pharmaceuticals, Regeneron Pharmaceuticals

Squamous Cell Carcinoma of the Oropharynx

06/24

12/24

PRINCESS, NCT05821751: The Effect of Prebiotic Inulin on Patients Affected by R/M HNSCC Treated With Immune Checkpoint Inhibitors

Recruiting

N/A

Europe

inulin, Pembrolizumab, Nivolumab

Fondazione del Piemonte per l'Oncologia, Ospedale Santa Croce-Carle Cuneo, Università degli Studi di Trento

Head and Neck Squamous Cell Carcinoma

12/24

12/25

Nuzzo, Annamaria

PRINCESS, NCT05821751: The Effect of Prebiotic Inulin on Patients Affected by R/M HNSCC Treated With Immune Checkpoint Inhibitors

Recruiting

N/A

Europe

inulin, Pembrolizumab, Nivolumab

Fondazione del Piemonte per l'Oncologia, Ospedale Santa Croce-Carle Cuneo, Università degli Studi di Trento

Head and Neck Squamous Cell Carcinoma

12/24

12/25

Checcucci, Enrico

RIDERS, NCT06318559: Artificial Intelligence 3D Augmented Reality Robot-Assisted-Radical- Prostatectomy v.s. no3D Intervention

Recruiting

N/A

120

Europe

3D Robot-assisted laparoscopic radical prostatectomy and pelvic lymphadenectomy

Fondazione del Piemonte per l'Oncologia, San Luigi Gonzaga Hospital

Cancer of Prostate

12/25

12/27

RETURN, NCT05832736: Robotic Hemi-Prostatectomy With Urethral Preservation in Low and Intermediate Risk Monolateral Prostate Cancer

Recruiting

N/A

Europe

Robotic hemi-prostatectomy with urethral preservation, Partial prostatectomy

Fondazione del Piemonte per l'Oncologia

Prostate Cancer

10/23

10/28

Staiano, Teresa

SunnyDay021, NCT06324032: SUNNYDAY: SUbepithelialgastroiNtestiNal Tumors Detection,accuracYDiAgnosis,ElastographY and Contrast-enhanced EUS

Recruiting

N/A

138

Europe

EUS Elastography (EUS-E), Endoscopic Ultrasound (EUS), Contrast Enhanced-EUS (CE-EUS)

Fondazione del Piemonte per l'Oncologia

Subepithelial Gastrointestinal Tumors

06/25

12/25

Rescigno, Pasquale

INSIDE, NCT06334809: Identification of Genomic Screening Pathways in Cancer Patients With DNA Repair Alterations

Recruiting

N/A

400

Europe

Fondazione del Piemonte per l'Oncologia

Prostate Cancer

12/26

12/27

Asioli, Marco

ACC Platform, NCT06339541: The ACC Preclinical Research Platform for Precision Oncology

Recruiting

N/A

250

Europe

Fondazione del Piemonte per l'Oncologia, Alleanza Contro il Cancro

Solid Tumor, Hematologic Neoplasms

06/24

12/24

Trial + Data / Events

Status

Region

Interventions

Sponsor

Conditions

Primary compl

Study compl

Montemurro, Filippo

Jan 2025 - Dec 2025: Pivotal data from ZEST trial for HER2-negative BRCA-mutated or triple-negative breast cancer

Active, not recruiting

Europe, Canada, Japan, US, RoW

Niraparib, Placebo

GlaxoSmithKline

Neoplasms, Breast

06/24

12/25

EMBER-4, NCT05514054: A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer

Recruiting

8000

Europe, Canada, Japan, US, RoW

Imlunestrant, LY3484356, Tamoxifen, Anastrozole, Letrozole, Exemestane

Eli Lilly and Company

Breast Neoplasms

10/27

03/32

Recruiting

168

Europe

Palbociclib

Consorzio Oncotech

Metastatic Breast Cancer, Locally Advanced Breast Cancer

07/23

BIO-META, NCT02284581: Evaluation of Medical Treatments in MBC Patients According Biological Subtype and Line of Treatments

Recruiting

N/A

10000

Europe

Consorzio Oncotech

Metastatic Breast Cancer

06/23

12/25

IRMO, NCT06337019: The Italian Registry of Malnutrition in Oncology

Recruiting

N/A

1500

Europe

Cohort observational

Fondazione IRCCS Policlinico San Matteo di Pavia, Istituto di Ricerche Farmacologiche Mario Negri IRCCS

Cancer, Cancer Metastatic

10/27

PREFER-Fertility, NCT02895165: PREgnancy and FERtility Registry

Recruiting

N/A

1000

Europe

IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy, Clinical Research Technology S.r.l.

Breast Neoplasms, Pregnancy, Fertility Preservation

11/27

11/32

Galizia, Danilo

XRAY VISION, NCT05386550 / 2022-001144-18: Phase III Xevinapant (Debio 1143) and Radiotherapy in Resected LA SCCHN, High Risk, Cisplatin-ineligible Participants

Terminated

166

Europe, Canada, Japan, US, RoW

Xevinapant (Debio 1143), IMRT, Placebo

EMD Serono Research & Development Institute, Inc., Merck KGaA, Darmstadt, Germany

Head and Neck Cancer

08/24

ProcemISA, NCT04398524 / 2020-003652-32: A Phase II Study of Cemiplimab and ISA101b in Patients With Recurrent/Metastatic HPV16 Positive OPC

May 2024 - Jul 2024 : Mid'24 - Data from ISA101b-OPC-03-19 study in recurrent metastatic HPV16 induced HNC

Active, not recruiting

Europe, US, RoW

ISA101b, Cemiplimab

ISA Pharmaceuticals, Regeneron Pharmaceuticals

Squamous Cell Carcinoma of the Oropharynx

06/24

12/24

PRINCESS, NCT05821751: The Effect of Prebiotic Inulin on Patients Affected by R/M HNSCC Treated With Immune Checkpoint Inhibitors

Recruiting

N/A

Europe

inulin, Pembrolizumab, Nivolumab

Fondazione del Piemonte per l'Oncologia, Ospedale Santa Croce-Carle Cuneo, Università degli Studi di Trento

Head and Neck Squamous Cell Carcinoma

12/24

12/25

Nuzzo, Annamaria

PRINCESS, NCT05821751: The Effect of Prebiotic Inulin on Patients Affected by R/M HNSCC Treated With Immune Checkpoint Inhibitors

Recruiting

N/A

Europe

inulin, Pembrolizumab, Nivolumab

Fondazione del Piemonte per l'Oncologia, Ospedale Santa Croce-Carle Cuneo, Università degli Studi di Trento

Head and Neck Squamous Cell Carcinoma

12/24

12/25

Checcucci, Enrico

RIDERS, NCT06318559: Artificial Intelligence 3D Augmented Reality Robot-Assisted-Radical- Prostatectomy v.s. no3D Intervention

Recruiting

N/A

120

Europe

3D Robot-assisted laparoscopic radical prostatectomy and pelvic lymphadenectomy

Fondazione del Piemonte per l'Oncologia, San Luigi Gonzaga Hospital

Cancer of Prostate

12/25

12/27

RETURN, NCT05832736: Robotic Hemi-Prostatectomy With Urethral Preservation in Low and Intermediate Risk Monolateral Prostate Cancer

Recruiting

N/A

Europe

Robotic hemi-prostatectomy with urethral preservation, Partial prostatectomy

Fondazione del Piemonte per l'Oncologia

Prostate Cancer

10/23

10/28

Staiano, Teresa

SunnyDay021, NCT06324032: SUNNYDAY: SUbepithelialgastroiNtestiNal Tumors Detection,accuracYDiAgnosis,ElastographY and Contrast-enhanced EUS

Recruiting

N/A

138

Europe

EUS Elastography (EUS-E), Endoscopic Ultrasound (EUS), Contrast Enhanced-EUS (CE-EUS)

Fondazione del Piemonte per l'Oncologia

Subepithelial Gastrointestinal Tumors

06/25

12/25

Rescigno, Pasquale

INSIDE, NCT06334809: Identification of Genomic Screening Pathways in Cancer Patients With DNA Repair Alterations

Recruiting

N/A

400

Europe

Fondazione del Piemonte per l'Oncologia

Prostate Cancer

12/26

12/27

Asioli, Marco

ACC Platform, NCT06339541: The ACC Preclinical Research Platform for Precision Oncology

Recruiting

N/A

250

Europe

Fondazione del Piemonte per l'Oncologia, Alleanza Contro il Cancro

Solid Tumor, Hematologic Neoplasms

06/24

12/24



	Diseases Companies Products Productz Mechanisms of Action Sites